ClinicalTrials.gg
CompletedNCT02121483Updated Sep 19, 2016Results posted

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

A Phase 1 interventional study of empagliflozin medium dose and empagliflozin high dose in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 11 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
92nd of 96
27 · median 302
Started
2014
with 6 others
Phase 1
19 of 130
none open now
Registered
80th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 92nd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2014, is one of 19 in phase 1, and was the 80th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents with type 2 diabetes mellitus
  • Insufficient glycaemic control ( \<=10.5%) despite diet and exercise and/or metformin and/or stable basal or MDI insulin
  • Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and fasting C-peptide levels >= 0.85 ng/ml
  • > 50th percentile for age and sex

Exclusion criteria

Exclusion criteria:

  • Uncontrolled hyperglycaemia with a glucose level > 240 mg/dl (> 13.3 mmol/l)
  • History of acute metabolic decompensation such as diabetic ketoacidosis within 3 months before the screening visit with the exception of acute de-compensation at the time of type 2 diabetes diagnosis
  • Treatment with weight reduction medications within 4 weeks before randomisation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    empagliflozin high dose

    Patient to receive a high dose of empagliflozin

    Drug: empagliflozin high dose

  • Experimental
    empagliflozin medium dose

    Patient to receive a medium dose of empagliflozin

    Drug: empagliflozin medium dose

  • Experimental
    empagliflozin low dose

    Patient to receive a low dose of empagliflozin

    Drug: empagliflozin low dose

Interventions

  • Drugempagliflozin medium dose
  • Drugempagliflozin high dose
  • Drugempagliflozin low dose
06

What researchers measure

Primary outcomes

  1. AUC0-inf

    Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).

    Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.

  2. AUC0-tz

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).

    Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.

  3. Cmax

    Maximum measured concentration in plasma (Cmax).

    Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.

  4. Tmax

    Maximum measured concentration in plasma (tmax).

    Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.

  5. t1/2

    Terminal half-life in plasma (t1/2).

    Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.

Secondary outcomes

  1. Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake

    Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake. For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'UGE at baseline' and 'FPG at baseline' as continuous covariates. Means presented are the adjusted means.

    Time frame: baseline and 24 hours

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake

    Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake. For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'FPG at baseline' as continuous covariate. Means presented are the adjusted means.

    Time frame: baseline and 24 hours

  3. Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake

    Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1). For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as fixed effect and 'MDG at baseline' as continuous covariate. Means presented are the adjusted means.

    Time frame: baseline and 24 hours

07

Results

Posted Sep 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Started9810
Completed9810
Not completed000

Outcome measures

PrimaryAUC0-inf

Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).

Time frame:
Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-inf
nmol*h/LEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
AUC0-inf1150 ± 47.61430 ± 17.25060 ± 29.5
Statistical analysis
  • Empagliflozin 5mg vs Empagliflozin 10mg vs Empagliflozin 25mg · Slope: 0.9490 · 95% CI 0.7276 to 1.1704Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and AUC0-inf. Based on the estimate for the slope parameter β, a 2-sided 95% confidence interval (CI) for the slope was computed.
PrimaryAUC0-tz

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).

Time frame:
Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-tz
nmol*h/LEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
AUC0-tz1110 ± 49.91400 ± 17.14980 ± 29.1
Statistical analysis
  • Empagliflozin 5mg vs Empagliflozin 10mg vs Empagliflozin 25mg · Slope: 0.9597 · 95% CI 0.7356 to 1.1838Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and AUC0-tz. Based on the estimate for the slope parameter β, a 2-sided 95% CI for the slope was computed.
PrimaryCmax

Maximum measured concentration in plasma (Cmax).

Time frame:
Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Reported as:
Geometric mean · nmol/L
Cmax
nmol/LEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Cmax159 ± 44.5188 ± 50.2602 ± 61.1
Statistical analysis
  • Empagliflozin 5mg vs Empagliflozin 10mg vs Empagliflozin 25mg · Slope: 0.8554 · 95% CI 0.5504 to 1.1603Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and Cmax. Based on the estimate for the slope parameter β, a 2-sided 95% CI for the slope was computed.
PrimaryTmax

Maximum measured concentration in plasma (tmax).

Time frame:
Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Reported as:
Median · hours
Tmax
hoursEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Tmax1.50 (0.95 to 7.92)1.25 (0.97 to 4.17)1.78 (0.50 to 4.00)
Primaryt1/2

Terminal half-life in plasma (t1/2).

Time frame:
Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Reported as:
Geometric mean · hours
t1/2
hoursEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
t1/26.92 ± 19.47.35 ± 29.37.80 ± 29.6
SecondaryChange From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake

Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake. For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'UGE at baseline' and 'FPG at baseline' as continuous covariates. Means presented are the adjusted means.

Time frame:
baseline and 24 hours
Reported as:
Mean · g/24h
Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake
g/24hEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake53.1 ± 10.2473.0 ± 10.1487.4 ± 9.39
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake

Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake. For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'FPG at baseline' as continuous covariate. Means presented are the adjusted means.

Time frame:
baseline and 24 hours
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake
mg/dLEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake-15.5 ± 6.53-16.6 ± 6.29-20.4 ± 5.68
SecondaryChange From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake

Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1). For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as fixed effect and 'MDG at baseline' as continuous covariate. Means presented are the adjusted means.

Time frame:
baseline and 24 hours
Reported as:
Mean · mg/dL
Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake
mg/dLEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake-12.9 ± 7.95-6.5 ± 9.21-13.2 ± 7.00

Adverse events

Collected over All adverse events reported within 7 days following trial drug administration were considered on treatment, up to 8 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin 5mg—0/9 (0%)4/9 (44.4%)
Empagliflozin 10mg—0/8 (0%)1/8 (12.5%)
Empagliflozin 25mg—0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventEmpagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mg
DehydrationMetabolism and nutrition disorders0/91/80/10
Anal pruritusGastrointestinal disorders1/90/80/10
VomitingGastrointestinal disorders1/90/80/10
NasopharyngitisInfections and infestations1/90/80/10
HeadacheNervous system disorders1/90/81/10
Abdominal painGastrointestinal disorders0/90/81/10
DiarrhoeaGastrointestinal disorders0/90/81/10
Ligament sprainInjury, poisoning and procedural complications0/90/81/10

Baseline characteristics

Treated Set (TS): The TS included all patients who were allocated trial medication and had received trial medication (empagliflozin).

Age, Continuous
Age, Continuous(Years)Empagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mgTotal
Mean13.7 ± 2.014.5 ± 1.914.2 ± 2.114.1 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 5mgEmpagliflozin 10mgEmpagliflozin 25mgTotal
Female65718
Male3339
08

Study locations

11 sites
  • 1245.87.01013 Boehringer Ingelheim Investigational Site
    New Haven, Connecticut, United States
  • 1245.87.01004 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts, United States
  • 1245.87.01002 Boehringer Ingelheim Investigational Site
    Toledo, Ohio, United States
  • 1245.87.01012 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1245.87.01001 Boehringer Ingelheim Investigational Site
    Pittsburgh, Pennsylvania, United States
  • 1245.87.33001 Boehringer Ingelheim Investigational Site
    Lyon, France
  • 1245.87.97202 Boehringer Ingelheim Investigational Site
    Beer Sheva, Israel
  • 1245.87.97203 Boehringer Ingelheim Investigational Site
    Tel Hashomer, Israel
  • 1245.87.52001 Boehringer Ingelheim Investigational Site
    Chihuahua, Mexico
  • 1245.87.27003 Boehringer Ingelheim Investigational Site
    Bellville, South Africa
  • 1245.87.27002 Boehringer Ingelheim Investigational Site
    Pretoria, South Africa
09

References and documents

Publications

  • Bjornstad P, Laffel L, Tamborlane WV, Simons G, Hantel S, von Eynatten M, George J, Marquard J, Cherney DZI. Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes. Diabetes Care. 2018 Aug;41(8):e129-e130. doi: 10.2337/dc18-0394. Epub 2018 Jun 25. No abstract available. PubMed 29941496 ↗
  • Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabet Med. 2018 Aug;35(8):1096-1104. doi: 10.1111/dme.13629. Epub 2018 May 6. PubMed 29655290 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 23, 2014
Start
Jun 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Sep 19, 2016
Last update
Sep 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02121483
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
Jun 2014
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Sep 19, 2016
Last update
Sep 19, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion